Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7097775 | 0.95 | SPHK2 (0.48) | OPRD1SPHK2SPHK1FAAH | |
| SCHEMBL11990419 | 0.89 | GBA1 (0.44) | OPRD1 | |
| SCHEMBL11969233 | 0.85 | OPRD1 (0.50) | OPRD1 | |
| SCHEMBL11990439 | 0.85 | OPRD1 (0.49) | OPRD1SPHK2SPHK1 | |
| SCHEMBL10682301 | 0.84 | OPRD1 (0.48) | OPRD1SPHK2SPHK1 | |
| SCHEMBL17274267 | 0.82 | OPRD1 (0.47) | OPRD1SPHK2SPHK1 | |
| SCHEMBL15481709 | 0.82 | OPRD1 (0.58) | OPRD1SPHK2SPHK1 | |
| Formic Acid SCHEMBL29201536 | 0.81 | OPRD1 (0.58) | OPRD1 | |
| SCHEMBL27492 | 0.81 | — | — | |
| SCHEMBL5967967 | 0.81 | OPRD1 (0.53) | OPRD1SPHK2SPHK1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3970723-A1 | AMINOINDANE COMPOUNDS FOR USE IN TREATING UROLOGICAL PAIN | Asana BioSciences, LLC (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3363437-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS SOLUTIONS (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3363437-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS SOLUTIONS (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-107540599-B | Aminoindane compounds and their use to treat pain | 阿萨纳生物科技有限责任公司 | 2021-06-04 | — | — | CN | disclosed |
| EP-3363437-A1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | Endo Pharmaceuticals Solutions Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-2675787-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-2675787-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| US-9375423-B2 | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis | ASANA BIOSCIENCES, LLC (US) | 2016-06-28 | — | — | US | disclosed |
| US-9375423-B2 | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis | ASANA BIOSCIENCES, LLC (US) | 2016-06-28 | — | — | US | disclosed |
| US-9375423-B2 | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis | ASANA BIOSCIENCES, LLC (US) | 2016-06-28 | — | — | US | disclosed |
| US-20140051702-A1 | Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis | ENDO PHARMACEUTICALS INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051702-A1 | Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis | ENDO PHARMACEUTICALS INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051702-A1 | Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis | ENDO PHARMACEUTICALS INC. (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2014028675-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | ENDO PHARMACEUTICALS INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| WO-2014028675-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | ENDO PHARMACEUTICALS INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| EP-2675787-A1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | Endo Pharmaceuticals Inc. (US) | 2013-12-25 | — | — | EP | disclosed |
| WO-2012112969-A1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| US-20120214809-A1 | Aminoindane Compounds and Use Thereof in Treating Pain | Libertas Bio, Inc. | 2012-08-23 | — | — | US | disclosed |
| US-20120214809-A1 | Aminoindane Compounds and Use Thereof in Treating Pain | Libertas Bio, Inc. | 2012-08-23 | — | — | US | disclosed |
| US-20120214809-A1 | Aminoindane Compounds and Use Thereof in Treating Pain | Libertas Bio, Inc. | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214809-A1 | Aminoindane Compounds and Use Thereof in Treating Pain | TRPA1, TRPV1, TRPV2 | OPRD1 47/4885SPHK2 1481/4885SPHK1 1085/4885 |
| US-20140051702-A1 | Use of Aminoindane Compounds in Treating Overactive Bladder and Interstitial Cystitis | IDO1, IDO2, SLC1A2 | OPRD1 51/4885SPHK2 2967/4885SPHK1 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.